Octreotide · source year
3 selected, source-linked Octreotide records carrying a 2021 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
3 selected records.
2 represented types.
3 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03734627 at 2026-07-30T19:59:58.328Z. Its registry update date was 2021-08-16, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2021-11575, attributed to FDA and its parent HHS department, on 2021-06-02. Its official title is “Determination That SANDOSTATIN (Octreotide Acetate) Injection, Equal to 0.2 Milligrams Base/Milliliter and Equal to 1 Milligrams Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.
Source: Federal Register via GovInfo ↗
Regulatory
The Federal Register published notice 2021-06202, attributed to FDA and its parent HHS department, on 2021-03-25. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Bremelanotide and Octreotide.
Source: Federal Register via GovInfo ↗